Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2024, for NanoVibronix, Inc. (the "Company"). The Company operates two primary business segments: Nano OpCo, which develops non-invasive ultrasound devices for pain therapy (PainShield), wound healing (WoundShield), and urinary catheter care (UroShield); and ENvue Medical, acquired via merger on February 14, 2025, which focuses on electromagnetic navigation systems for enteral feeding tube insertion. The filing notes that the financial statements do not reflect the consummation of the merger with ENvue, which occurred subsequent to the reporting period.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $2,558,000 | $2,283,000 |
| Gross Profit | $1,508,000 | $1,537,000 |
| Gross Margin | 59% | 67% |
| Net Loss | $(3,705,000) | $(3,711,000) |
| Cash and Cash Equivalents (Year End) | $752,000 | $3,283,000 |
| Operating Cash Flow | $(2,516,000) | $(3,602,000) |
| Accumulated Deficit | $(69,801,000) | $(66,096,000) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by approximately 12% ($275,000) year-over-year, driven by increased sales to Veteran Administration facilities and the largest direct distributor, Ultra Pain Products Inc. (31% of 2024 revenue).
- Gross Margin Compression: Gross margin decreased from 67% to 59% due to lower wholesale pricing awarded to specific government and workers' compensation customers effective in Q2 2024.
- R&D Spike: Research and development expenses surged 391% to $909,000, primarily due to a new product development project and a clinical trial with the University of Michigan.
- Cash Position: Cash reserves declined significantly from $3.28 million to $752,000, reflecting continued operating losses and negative cash flow from operations.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
Management has expressed substantial doubt about the Company's ability to continue as a going concern. With a cash balance of $752,000 and negative operating cash flow, the Company does not have sufficient resources to fund operations for the next twelve months without raising additional capital. Future viability depends on successful commercialization of products and securing equity or debt financing.
Recent Developments (Subsequent Events)
- Merger with ENvue: On February 14, 2025, the Company completed a merger with ENvue Medical Holdings, Corp. Consideration included 1,734,995 common shares and 57,720 shares of Series X Non-Voting Convertible Preferred Stock.
- Debt Financing: In February 2025, the Company issued a senior convertible debenture initially for $500,000, later amended in March 2025 to $1,300,000, bearing 8.0% interest.
- Reverse Stock Split: A 1-for-11 reverse stock split became effective on March 13, 2025, to regain compliance with Nasdaq listing requirements.
Key Risks
- Liquidity: Immediate need for capital to sustain operations.
- Regulatory: UroShield sales in the U.S. were conducted under FDA Enforcement Discretion during the pandemic; the Company has ceased U.S. sales pending permanent clearance. PainShield reimbursement from CMS was denied in 2023 pending additional testing.
- Legal: An arbitration award of approximately $2.1 million (accrued as of Dec 31, 2024) remains outstanding against the Company regarding a dispute with Protrade Systems, Inc., currently on appeal.
- Geopolitical: Operations in Israel face risks from regional conflict, including potential supply chain disruptions and employee mobilization.
Investor Verification Checklist
- Capital Adequacy: Verify the status of the $1.3 million debenture and any subsequent equity raises to confirm the Company can meet its 12-month liquidity needs.
- Merger Integration: Review the terms of the ENvue merger, specifically the conversion mechanics of the Series X Preferred Stock and the impact on existing shareholder dilution.
- Legal Liability: Monitor the status of the Protrade arbitration appeal, as a final adverse ruling could require a cash payment exceeding current cash reserves.
- Regulatory Status: Confirm the current status of FDA clearance for UroShield and the resubmission strategy for PainShield reimbursement with CMS.
- Nasdaq Compliance: Verify that the reverse stock split successfully restored compliance with Nasdaq minimum bid price and equity requirements.